BioSpace News Archive

Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the presentation of a Trials in Progress poster for the ongoing seamless Phase 1/2 clinical trial of FLX475, a small molecule CCR4 antagonist in developm

The treatment for lung infections has conventionally been led by small molecule therapies.

The global interferons market is predicted to rise at a steady growth rate in the forthcoming years.

Eyecarrot Innovations Corp (FRA:2EYA:GR] announces the appointment of Dr. Leonard Press to Chief Scientific Officer.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced the appointment of Dr. Jack Reich to the Board of Directors. The appointment increases the Board to seven members.

IONIQ Sciences Inc., announced it is initiating an institutional private equity offering on the heels of receiving ‘Breakthrough Device Designation’ from the U.S. FDA for its lung cancer test.

XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan

Novus Acquisition and Development, Corp., through its wholly-owned subsidiary WCIG Insurance Services, Inc., is an insurance entity in health and, the nation’s first carrier offering cannabis health plans to recreation and medicinal users, reported, its financial and operational results for the three months ended March 31, 2020.

Hansa Biopharma appoints Professor Achim Kaufhold, M.D., a highly experienced senior leader in immunology, infectious diseases and oncology, as Chief Medical Officer.